UnknownPhase 4

Efficacy of Linaclotide in Patients With Overlapping Functional Gastrointestinal Disorders

China78 participantsStarted 2021-01-01

Plain-language summary

This study aims to assess the efficacy and safety of linaclotide in patients with overlapping symptoms of both functional dyspepsia (FD) and constipation-predominant irritable bowel syndrome (IBS-C).

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Outpatients
✓. Diagnosis of FD (including postprandial distress syndrome \[PDS\] with or without epigastric pain syndrome \[EPS\]) (Rome Ⅲ criteria)
✓. Diagnosis of IBS-C (Rome Ⅲ criteria)

Exclusion criteria

✕. Helicobacter Pylori infection
✕. GI symptoms caused by taking non-steroidal anti-inflammatory drugs or other agents
✕. Pregnancy

What they're measuring

Treatment satisfaction assessed by the VAS

Timeframe: Week 4

Trial details

NCT IDNCT05134584

SponsorRenJi Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-12

Contact for this trial

Shengliang Chen

86-21-58752345 chenslmd@163.com

View on ClinicalTrials.gov More Functional Dyspepsia trials